Our mission is to accelerate cures for kidney cancer. We engage in patient advocacy and power research by supporting government and industry research funding, facilitating research collaborations, and offering direct financial support for clinical and laboratory researchers with promising ideas. Together, we can find the cure.
You’re not alone. We’ve put together a Patient Resource Center to help you navigate a new diagnosis and beyond. Learn about kidney cancer, various treatment options, patient education events, and how to live well with cancer.
Awareness? Funding? Research? Cures?
Follow Us!
This prestigious award supports early career scientists advancing innovative cancer immunotherapy research, with the recipient receiving $150,000 in research funding and recognition at the SITC 2026 Annual Meeting.
Nominations are due June 12, 2026.
Learn more and apply:
Today, on National Cancer Survivors Day, we celebrate the strength, resilience, and determination of cancer survivors everywhere.
Every survivor's journey is unique. Some are newly diagnosed, some are years beyond treatment, and others continue to navigate cancer as an ongoing
An interesting read from our friend @arihakimi @MSKCancerCenter and his group tackling probably the most important question in 1L cRCC: IO/IO vs VEGF/IO. Bravo Ari and team! this will be the weekend read before @FIFAWorldCup starts next week.
@kaelin_lab @LabSignoretti
Fellowships like this are crucial for retaining talent! While Spain struggles with chronic underfunding, the UAE is investing seriously in biotech professionals. 🧬🚀
Supporting the next generation of #KidneyCancer researchers is critical to #AcceleratingCures.
The AACR-Exelixis Renal Cell Carcinoma Research Fellowship provides funding and support for promising early-career investigators pursuing RCC research.
Apply by June 11:
Neoadjuvant TKI trials in RCC taught us an important lesson.
Feasible? Yes.
Some tumor shrinkage? Yes.
Pathologic CR? Rare.
Long-term data? Limited.
The question is not “can we give it?”
It is “does it change the operation, the outcome, or the patient’s life?”
...#ASCO26
@DrChoueiri
At #ASCO26, @kashimamdphd @BraunMDPhD share why some #kidneycancer tumors don’t respond to immunotherapy despite having plenty of T cells. Research found many T cells are “exhausted” and unable to fight cancer effectively, likely due to TGF-β signaling. Blocking TGF-β1 helped
Proud of @charlesbnguyen @cityofhope who just gave a phenomenal overview of #papillary #kidneycancer therapy at #ASCO26. He has been building an impressive portfolio of studies at @cityofhopeoc in GU cancers! Great perspectives shown today including data from @DrChoueiri,
Excited to share our #ASCO2026 poster presentation by our postdoc alumni @BetulGokYavuz1
@UChicago 🌟 physician👩⚕️👩🔬scientist Heme/Onc fellow. Deciphering the Genomic Landscape of Renal Cell Carcinoma Brain Metastases
📜https://t.co/rcDdIWfiVl
📽️ ...https://t.co/xUfuKc0zUM
This
KidneyCAN is a registered 501(c)(3) nonprofit and does not receive any funding through the Congressionally Directed Medical Research Program (CDMRP) or KCRP (Kidney Cancer Research Program). Our work is funded by grassroots donors in the kidney cancer community.
